share_log

B of A Securities Downgrades Esperion Therapeutics to Underperform, Lowers Price Target to $2.5

Benzinga ·  Jun 20 18:36

B of A Securities analyst Jason Zemansky downgrades Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Underperform and lowers the price target from $2.9 to $2.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment